EU GMP Annex 1 (2022) Explained for Cannabis Manufacturers

Overview

The 2022 revision of EU GMP Annex 1 — Manufacture of Sterile Medicinal Products — represents the most significant update to sterile manufacturing guidance in over a decade. While the primary focus of Annex 1 is sterile product manufacture, its requirements extend to all medicinal product manufacturers in several critical areas — most importantly the Contamination Control Strategy requirement now in Clause 4.4.

This commentary explains what changed in 2022 and what pharmaceutical cannabis manufacturers specifically need to understand and implement.

1. The Contamination Control Strategy — Clause 4.4

The most significant new requirement introduced by the 2022 revision for non-sterile manufacturers is the formal Contamination Control Strategy (CCS). Clause 4.4 requires that:

"A contamination control strategy should be implemented across the facility to define all the critical control points and assess the effectiveness of all the controls (design, procedural, technical and organisational) and monitoring measures employed to manage risks to product and environmental quality."

For pharmaceutical cannabis manufacturers, this means producing a formal CCS document that:

• Identifies all contamination sources relevant to the facility and products
• Maps contamination pathways — how each source could reach the product
• Assesses the risk of each contamination pathway using a risk management methodology (typically FMEA)
• Identifies all controls in place to manage each risk
• Demonstrates how monitoring provides ongoing assurance that controls remain effective
• Is reviewed whenever significant changes are made and at defined periodic intervals

The CCS is not a checklist or a summary of existing procedures. It is a strategic document that demonstrates how all the individual contamination control measures in the facility collectively constitute an integrated contamination control system.

2. What Changed from 2008 to 2022

3. Implications for Cannabis Manufacturing Classified Areas

Many pharmaceutical cannabis manufacturing operations include classified areas — typically Grade C for formulation and filling operations, and Grade D for extraction and processing. The 2022 Annex 1 requirements apply to these areas, even where the products are non-sterile.

Smoke studies

The 2022 revision requires that airflow visualisation studies be conducted under in-operation conditions, with the maximum intended number of personnel present, and with video recording. For cannabis facilities that conducted smoke studies under at-rest conditions only, repeat studies under in-operation conditions are required.

Gowning

The 2022 revision expands on gowning requirements, including the specific requirement that gowning be qualified — not just described in a procedure. Gowning qualification typically involves finger-dab and settle plate sampling immediately post-gowning to demonstrate that the gowning procedure does not itself introduce contamination.

Environmental monitoring frequency

The 2022 revision requires that EM sampling frequency be justified based on the level of risk in each area and the production activities conducted. For Grade C areas where cannabis is formulated, sampling should occur at minimum during each production campaign.

4. Implementation Priorities for Cannabis Manufacturers

1. Produce or update the Contamination Control Strategy. If no formal CCS exists, one must be produced. If a CCS exists but was written before the 2022 revision, it should be reviewed against the new requirements — particularly the FMEA-based risk assessment and the cannabis-specific contamination pathway requirements.
2. Review smoke study status. If smoke studies were conducted under at-rest conditions only, schedule repeat studies under in-operation conditions with video recording.
3. Review gowning qualification. Ensure gowning qualification includes post-gowning microbiological sampling and is documented as a formal qualification activity.
4. Review EM alert and action limits. If limits were set by reference to grade limits rather than facility-specific baseline data, the EMPQ should be reviewed and limits recalculated from actual data.
5. Review EM sampling frequency justification. Ensure the EMPQ documents the risk-based rationale for each sampling location and frequency.

5. References

• EU GMP Annex 1 (2022) — Manufacture of Sterile Medicinal Products. Official Journal of the European Union, August 2022.
• EMA. Q&A on the Revised EU GMP Annex 1 (published September 2022).
• PIC/S. Recommendation on the Validation of Aseptic Processes (PI 007-6, 2011).
• ISPE. Baseline Guide Vol. 6 — Biopharmaceutical Manufacturing Facilities (3rd Edition).
• ISO 14644-1:2015 — Classification of Air Cleanliness by Particle Concentration.